Advances in molecular genetics

American Journal of Surgery

Volumn 173, Issue 1, 1997, Pages 37-41

  Lairmore, Terry C ^a   Norton, Jeffrey A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME 18Q; CHROMOSOME LOSS; COLORECTAL CARCINOMA; FAMILIAL CANCER; FAMILIAL POLYPOSIS; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC SUSCEPTIBILITY; HUMAN; METASTASIS POTENTIAL; MUIR TORRE SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031044626     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00363-7     Document Type: Article

References (15)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
2. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102-105.
3. Jin J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. NEJM. 1994;331:213-221.
4. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell. 1994;77:175-178.
5. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics 1994;6:70-74.
6. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-383.
7. Wells SA Jr., Chi D, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220:237-250.
8. Hahn SA, Schutte M, Shamsul Hoque ATM, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q 21.1. Science. 1996;271:350-352.
9. Whelan AJ, Bartsch D, Goodfellow PJ. Brief Report: A Familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor suppressor gene. NEJM. 1995;333:975-977.
10. Bartsch D, Shevlin DW, Gallery MP, et al. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst. 1996;88:680-682.
11. Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcoma and other neoplasms. Science. 1990;250:1233-1238.
12. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
13. Wooster R, Neuhausen SL, Mangion J, et al. Localization of breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088-2090.
14. Wooster R, Bignall G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-791.
15. Honchel R, Halling KC, Schaid DJ, et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res. 1994;54:1159-1163.